Unveiling the Anticancer Mechanisms of Prodigiosin by inhibiting of CDK1, TOP2A, and AURKB Expression in Cervical Carcinoma

Abstract

Abstract Prodigiosin (PG) demonstrates a selective targeting effect on tumor cells. However, its role in cervical carcinoma is still being studied. In this study, we aim to study the specific targets and mechanism of PG in cervical carcinoma. We employed GO enrichment and KEGG analysis to identify core genes in CC patients. To corroborate the expression levels of these core genes, we used staining and RT-PCR on both normal and tumor tissues. Following this, the specific effects of PG on Hela, H8, and A549 cells were compared. After PG treatment, cell viability was evaluated using a CCK8 assay at various PG concentrations. Apoptosis in Hela cells was determined through flow cytometry post-PG treatment, and the expression of target genes was measured via RT-PCR. Our analysis highlighted CDK1, TOP2A, and AURKB emerging as core genes. The expression of CDK1, TOP2A, and AURKB, both at the protein and gene levels, was found to be higher in cervical carcinoma tissues compared to controls. Furthermore, lower PG concentrations diminished the viability of Hela and A549 cells without significantly impacting H8 cells. PG was observed to induce apoptosis in Hela cells by reducing the expression of CDK1, TOP2A, and AURKB genes.